deCODE Genetics Submits IPO Prospectus Highlighting Large-Scale Plasma Proteogenomic Insights from UK and Icelandic Populations

TodayIn a published paper,deCODE GeneticsThe scientist shared hisWe used the results of plasma proteomics research based on affinity methods. HeWe analyzed proteins in the context of disease and diversity within genomic sequences and compared the results of thousands of proteins measured using two platforms, with samples coming from large cohorts in the UK Biobank and Iceland.

Reykjavik, IcelandOctober 4, 2023PR Newswire -- Today, scientists at deCODE Genetics, a subsidiary of Amgen, Inc.NatureDemonstrates how plasma proteomics can help understand diseases. The research team focused on the plasma proteome and discovered associations between various diseases and specific protein levels. One of the senior authors of the paper is a scientist from deCODE genetics.Patrick Sulem"In population-based groups, measuring a large number of proteins can identify biomarkers in circulation and enable early disease detection."

In addition, scientists also use genetic factors that influence protein levels to clarify the biological connections between sequence variation associations and the causes of diseases. "The biological relationship between sequence variation and disease is often elusive. Incorporating proteomics into the analysis can reveal the molecular mechanisms of disease development," said a scientist from deCODE genetics.Kári StefánssonRepresentation.

Scientists analyzed data from approximately 50,000 individuals of European, African, and Asian ancestry from the UK Biobank using the Olink Explore platform's 2,941 immunoassays. This data was generated by the UK Biobank Pharmaceutical Proteomics Project (UKB-PPP), a consortium of 13 biopharmaceutical companies including Amgen, aimed at researching biomarkers of circulating proteins. The authors compared these findings with those from a previous study in which they analyzed data from approximately 40,000 Icelanders using 4,907 aptamer-based assays on the SomaScan platform. In total, they identified over 80,000 associations between sequence variants and protein levels, as well as more than 500,000 associations involving diseases and other protein-level traits.

Scientists observed discrepancies in protein-level measurements when using two platforms to examine a subset of samples. The differences between these platforms impacted the discovery of circulating disease biomarkers, as well as the detection of genetic factors influencing both protein levels and disease manifestations. By studying large populations in Iceland and the UK, numerous associations could be identified, making the comparison results more significant. The authors emphasized the value of analyzing cases individually.

Kári Stefánsson, CEO of deCODE genetics and one of the senior authors of the paper, stated: "While these two proteomics platforms are practical tools for simultaneously testing thousands of proteins in large datasets, we still need to carefully validate individual proteins."

deCODEHeadquartered in Reykjavik, Iceland, it is a global leader in analyzing and understanding the human genome. Utilizing its uniqueProfessional knowledge and human resources,deCODEAlreadyDozens of genetic risk factors for common diseases have been discovered. Understanding Disease GenomicsIn order to use this information to establish new ways for diagnosing, treating, and preventing diseases.deCODEAmgen(Nasdaq: AMGN) NationwideSubsidiary.